Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Cash & Current Investments (2023 - 2025)

Mangoceuticals' Cash & Current Investments history spans 3 years, with the latest figure at $498223.0 for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 2840.76% year-over-year to $498223.0; the TTM value through Sep 2025 reached $498223.0, up 2840.76%, while the annual FY2024 figure was $16942.0, 0.0% changed from the prior year.
  • Cash & Current Investments for Q3 2025 was $498223.0 at Mangoceuticals, up from $117961.0 in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $3.8 million in Q1 2023 and bottomed at $16942.0 in Q4 2023.
  • The 3-year median for Cash & Current Investments is $67451.5 (2023), against an average of $713989.4.
  • The largest annual shift saw Cash & Current Investments plummeted 98.63% in 2024 before it surged 2840.76% in 2025.
  • A 3-year view of Cash & Current Investments shows it stood at $16942.0 in 2023, then changed by 0.0% to $16942.0 in 2024, then soared by 2840.76% to $498223.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Cash & Current Investments are $498223.0 (Q3 2025), $117961.0 (Q2 2025), and $16942.0 (Q1 2025).